Quantcast

Latest antibodies Stories

2014-07-01 08:29:55

Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer THOUSAND OAKS, Calif., July 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational bispecific T cell engager (BiTE(®)) antibody blinatumomab, for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly...

2014-06-26 23:02:12

Dr. Arash Bereliani, the founder of the IV Therapy Center in Beverly Hills, spoke recently about a new study showing that intravenous vitamin C is useful for patients with Epstein-Barr virus antibodies. Beverly Hills, CA (PRWEB) June 26, 2014 A new study published in the journal Medical Science Monitor has found that patients who have high levels of Epstein-Barr virus (EBV) antibodies can benefit from intravenous vitamin C. The researchers, Nina A. Mikirova and Ronald Hunninghake of...

2014-06-25 08:32:07

SAN DIEGO, June 25, 2014 /PRNewswire/ -- Concortis Biosystems, Inc. (Concortis), a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced a collaboration to generate novel antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis' proprietary ADC Technology. Under the terms of the agreement, Sorrento will receive...

2014-06-18 23:16:14

Bacterial recombinant protein expression is now available as a service at Maine Biotechnology Services. When MBS develops recombinant antigen for a hybridoma development, the end use application of the antibodies is considered during every phase of antigen production. Portland, Maine (PRWEB) June 18, 2014 Maine Biotechnology Services is announcing the addition of Bacterial Recombinant Protein Expression and Purification services to compliment our complete antibody service offering, adding...

2014-06-18 04:21:10

-- 3SBio's pegsiticase has shown a promising efficacy and safety profile in early clinical trials and Selecta and 3SBio plan to advance clinical studies of pegsiticase-based treatments for refractory and tophaceous gout as well as tumor lysis syndrome SHENYANG, China, June 18, 2014 /PRNewswire/ -- 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered...

2014-06-12 23:05:29

The newly released Pre-Sure ChIP Antibody Validation Kit is a fast, affordable, and robust method for ChIP-grade validation of antibodies for use in ChIP-PCR, ChIP-on-chip, and ChIP-seq. Farmingdale, NY (PRWEB) June 12, 2014 Epigentek today announced the debut of Pre-Sure(TM), a commercialized kit for quickly validating and qualifying whether antibodies are suitable for use in chromatin immunoprecipitation (ChIP). Officially known as the Pre-Sure(TM) ChIP Antibody Validation Kit, the...

2014-06-12 23:04:03

Ion Exchange Chromatography Reagents market can be segmented by Companies, Geographies, Applications, Products, Technologies and End Users. http://www.micromarketmonitor.com/market-report/ion-exchange-chromatography-reagents-reports-9812782514.html (PRWEB) June 12, 2014 The global ion exchange chromatography reagents market is projected to grow at a CAGR of about 11.0% from 2013 to 2018. Increased support from governments’ worldwide, increased usage of chromatographic techniques in the...

2014-06-11 23:13:29

New England Peptide and SISCAPA expand commercialization of mass spec biomarker assays. Gardner, MA (PRWEB) June 11, 2014 Today, New England Peptide, Inc. (NEP) and SISCAPA Assay Technologies, Inc. (SAT) announced a collaboration for the manufacture and sale of Stable Isotope Standard (SIS) peptides for use in SISCAPA® protein quantification assays. Under the terms of the agreement, NEP will manufacture peptide standards suitable for use with SAT’s SISCAPA assays. The peptides will...

2014-06-11 08:29:19

LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ -- RuiYi, Inc., a global therapeutic innovation leader, announced today the close of a $4 million debt financing from Silicon Valley Bank to advance a pipeline of novel monoclonal antibodies (mAb) targeting G protein coupled receptors (GPCRs). RuiYi plans to file an IND and initiate clinical trials in multiple countries in 2015 for the company's lead asset, RYI-008, a novel anti-IL-6 mAb for rheumatoid arthritis and cancer....

2014-06-11 08:29:17

New antibodies generated with RuiYi's iCAPS technology to explore GPCR structure and function LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ -- RuiYi, a global therapeutic innovation leader, and iHuman Institute at ShanghaiTech University announced today a new research collaboration applying RuiYi's iCAPS (Intermembranous Conformation Antigen Presenting System) technology to create novel monoclonal antibodies with specific binding to G protein coupled receptors (GPCRs) to...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related